BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25735341)

  • 1. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
    Prasaja Y; Sutandyo N; Andrajati R
    Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy.
    Kos FT; Sendur MA; Aksoy S; Celik HT; Sezer S; Civelek B; Yaman S; Zengin N
    Asian Pac J Cancer Prev; 2013; 14(2):1111-4. PubMed ID: 23621196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
    Merouani A; Davidson SA; Schrier RW
    Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal tolerance to cisplatin in patients 70 years and older.
    Cubillo A; Cornide M; López JL; Molina R; Feliu J; Espinosa E; Zamora P; de Castro J; Ordoñez A; González Barón M
    Am J Clin Oncol; 2001 Apr; 24(2):192-7. PubMed ID: 11319297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
    Losonczy G; Máthé C; Müller V; Szondy K; Moldvay J
    Magy Onkol; 2010 Dec; 54(4):289-96. PubMed ID: 21163759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
    Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
    J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Renal Outcomes after Cisplatin Treatment.
    Latcha S; Jaimes EA; Patil S; Glezerman IG; Mehta S; Flombaum CD
    Clin J Am Soc Nephrol; 2016 Jul; 11(7):1173-1179. PubMed ID: 27073199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.
    Minzi OMS; Lyimo TE; Furia FF; Marealle AI; Kilonzi M; Bwire GM; Malichewe C
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):69. PubMed ID: 32967726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study.
    Inoue T; Miyazaki J; Ichioka D; Narita S; Kageyama S; Sugimoto M; Mitsuzuka K; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Matsui Y; Fujie K; Habuchi T; Nishiyama H
    BMC Cancer; 2018 Mar; 18(1):290. PubMed ID: 29540229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
    Shord SS; Thompson DM; Krempl GA; Hanigan MH
    Anticancer Drugs; 2006 Feb; 17(2):207-15. PubMed ID: 16428940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
    Hinai Y; Motoyama S; Niioka T; Miura M
    J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
    Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
    PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
    Jiménez-Triana CA; Castelán-Martínez OD; Rivas-Ruiz R; Jiménez-Méndez R; Medina A; Clark P; Rassekh R; Castañeda-Hernández G; Carleton B; Medeiros M;
    Medicine (Baltimore); 2015 Aug; 94(34):e1413. PubMed ID: 26313789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
    Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
    Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
    Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
    J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity.
    Sendur MA; Aksoy S; Yaman S; Arik Z; Tugba Kos F; Akinci MB; Civelek B; Yildirim Ozdemir N; Uncu D; Zengin N
    J BUON; 2013; 18(1):274-80. PubMed ID: 23613416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
    Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
    Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.